ES2963348T3 - Métodos para tratar la osificación heterotópica - Google Patents

Métodos para tratar la osificación heterotópica Download PDF

Info

Publication number
ES2963348T3
ES2963348T3 ES17809505T ES17809505T ES2963348T3 ES 2963348 T3 ES2963348 T3 ES 2963348T3 ES 17809505 T ES17809505 T ES 17809505T ES 17809505 T ES17809505 T ES 17809505T ES 2963348 T3 ES2963348 T3 ES 2963348T3
Authority
ES
Spain
Prior art keywords
subject
days
palovarotene
flare
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17809505T
Other languages
English (en)
Spanish (es)
Inventor
Clarissa Desjardins
Donna Roy Grogan
Jeffrey Neal Packman
Mark Harnett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clementia Pharmaceuticals Inc
Original Assignee
Clementia Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clementia Pharmaceuticals Inc filed Critical Clementia Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2963348T3 publication Critical patent/ES2963348T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES17809505T 2016-06-08 2017-06-08 Métodos para tratar la osificación heterotópica Active ES2963348T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662347381P 2016-06-08 2016-06-08
PCT/CA2017/050701 WO2017210792A1 (en) 2016-06-08 2017-06-08 Methods for treating heterotopic ossification

Publications (1)

Publication Number Publication Date
ES2963348T3 true ES2963348T3 (es) 2024-03-26

Family

ID=60578331

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17809505T Active ES2963348T3 (es) 2016-06-08 2017-06-08 Métodos para tratar la osificación heterotópica

Country Status (18)

Country Link
US (6) US10864194B2 (enExample)
EP (2) EP3468554B1 (enExample)
JP (2) JP7023868B2 (enExample)
KR (1) KR102486607B1 (enExample)
CN (2) CN109562099A (enExample)
AU (2) AU2017276835B2 (enExample)
BR (1) BR112018075422A2 (enExample)
CA (1) CA3025854A1 (enExample)
CL (1) CL2018003502A1 (enExample)
EA (1) EA201892497A1 (enExample)
ES (1) ES2963348T3 (enExample)
IL (3) IL263440B (enExample)
MX (2) MX390115B (enExample)
MY (1) MY200642A (enExample)
PH (1) PH12018502563A1 (enExample)
SG (1) SG11201810658PA (enExample)
WO (1) WO2017210792A1 (enExample)
ZA (1) ZA201808102B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111773213B (zh) 2010-09-01 2023-02-24 托马斯杰弗逊大学 用于肌肉修复和再生的组合物和方法
ES2963348T3 (es) * 2016-06-08 2024-03-26 Clementia Pharmaceuticals Inc Métodos para tratar la osificación heterotópica
JP7018957B2 (ja) 2016-11-16 2022-02-14 クレメンティア ファーマシューティカルズ インコーポレイテッド 多発性骨軟骨腫（ｍｏ）を処置するための方法
WO2020118405A1 (en) * 2018-12-13 2020-06-18 Clementia Pharmaceuticals Inc. Methods for treating heterotopic ossification
EP4186505A4 (en) * 2020-06-11 2024-06-19 Yang Sheng Tang Company, Ltd. USE OF PALOVAROTEN TO TREAT HBV VIRUS
EP4470537A1 (en) * 2023-05-30 2024-12-04 Queen's University At Kingston Compound for use in treating fibrodysplasia ossificans progressiva (fop)
EP4470536A1 (en) * 2023-05-30 2024-12-04 Queen's University At Kingston Compound for use in treating fibrodysplasia ossificans progressiva (fop)
CN119185298B (zh) * 2024-10-30 2025-09-26 武汉大学人民医院（湖北省人民医院） 帕罗伐汀在制备用于治疗脑出血后急性脑损伤的药物中的应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824685A (en) 1995-02-01 1998-10-20 The Johns Hopkins University School Of Medicine Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
US5624957A (en) 1995-06-06 1997-04-29 Bristol-Myers Squibb Company Rary-specific retinobenzoic acid derivatives
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
US7514074B2 (en) 1997-07-14 2009-04-07 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
US6204288B1 (en) 1999-03-08 2001-03-20 The University Of Mississippi 1,2-dithiolane derivatives
US20030114482A1 (en) 1999-12-15 2003-06-19 Maurizio Pacifici Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
US6313168B1 (en) 1999-12-15 2001-11-06 Allergan Sales, Inc. Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
CA2402413A1 (en) 2000-03-14 2001-09-20 The University Of Western Ontario Compositions and methods for affecting osteogenesis
WO2002028810A2 (en) 2000-10-02 2002-04-11 F. Hoffmann-La Roche Ag Retinoids for the treatment of emphysema
BR0212583A (pt) 2001-09-18 2004-10-13 Hoffmann La Roche Agonistas i para retinóides de alquil uréia
AU2002340886B2 (en) 2001-09-18 2008-01-31 F. Hoffmann-La Roche Ag Substituted urea retinoid agonists II
AUPR892501A0 (en) 2001-11-16 2001-12-13 Peter Maccallum Cancer Institute, The Method of enhancing self renewal of stem cells and uses thereof
US20050101581A1 (en) 2002-08-28 2005-05-12 Reading Christopher L. Therapeutic treatment methods 2
JP2005206544A (ja) 2004-01-23 2005-08-04 Yasuyoshi Uchida 筋肉再生剤
AU2005240078A1 (en) 2004-04-30 2005-11-17 Allergan, Inc. Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing
WO2005115304A2 (en) 2004-05-24 2005-12-08 Ab Science Use of c-kit inhibitors for treating fibrodysplasia
US20060210638A1 (en) 2005-03-17 2006-09-21 Elan Pharma International Limited Injectable compositions of nanoparticulate immunosuppressive compounds
US7345931B2 (en) 2005-08-01 2008-03-18 Infineon Technologies Ag Maintaining internal voltages of an integrated circuit in response to a clocked standby mode
US20090281184A1 (en) 2005-09-27 2009-11-12 Sapporo Medical University Pharmaceutical for prevention and treatment of ophthalmic disease induced by in-crease in vasopermeability
US20070213308A1 (en) * 2006-01-26 2007-09-13 Lessem Jan N Methods, compositions, and kits for the treatment of musculoskeletal disorders and symptoms associated therewith
CA2647275A1 (en) 2006-03-31 2007-10-11 F. Hoffmann-La Roche Ag Process for preparing retinoid compounds
CN101472572B (zh) 2006-05-16 2012-10-10 Io治疗有限责任公司 Rar拮抗剂或反向激动剂在治疗化学疗法和/或放射疗法副作用中的用途
US8614103B2 (en) 2006-10-27 2013-12-24 Lpath, Inc. Compositions and methods for treating sphingosine-1-phosphate (S1P) related ocular diseases and conditions
US9119777B2 (en) 2008-05-30 2015-09-01 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
EP2265603B1 (en) 2008-03-13 2014-05-07 The General Hospital Corporation Inhibitors of the bmp signaling pathway
JP2009235031A (ja) 2008-03-28 2009-10-15 Nano Egg:Kk 角膜組織の再生促進剤
EP2379174A4 (en) 2008-12-18 2012-11-14 Astrazeneca Ab PHARMACEUTICAL PRODUCT USING A P38 KINASE INHIBITOR AND A SECOND ACTIVE SUBSTANCE
WO2010088735A1 (en) 2009-02-05 2010-08-12 Regenertech Pty Ltd Method of producing progenitor cells from differentiated cells
US20120277156A1 (en) * 2009-07-21 2012-11-01 University Of Washington Trhough It's Center For Commercialization Inhibition of pathological bone formation
CN111773213B (zh) 2010-09-01 2023-02-24 托马斯杰弗逊大学 用于肌肉修复和再生的组合物和方法
US20120077786A1 (en) 2010-09-27 2012-03-29 Byron David A Methods and compositions for disease treatment using inhalation
WO2012125724A1 (en) 2011-03-14 2012-09-20 Beth Israel Deaconess Medical Center Methods and compositions for the treatment of proliferative disorders
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
WO2013006372A1 (en) * 2011-07-01 2013-01-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of treating pathologic heterotopic ossification
US8772273B2 (en) 2011-10-04 2014-07-08 Quretino Therapeutics, Inc. Formulations and uses of retinoic acid receptor selective agonists
AU2013222345B2 (en) * 2012-02-22 2017-09-07 Sanford-Burnham Medical Research Institute Sulfonamide compounds and uses as TNAP inhibitors
JP6430383B2 (ja) 2012-09-28 2018-11-28 ヴァンダービルト ユニバーシティーＶａｎｄｅｒｂｉｌｔ Ｕｎｉｖｅｒｓｉｔｙ 選択的ｂｍｐ阻害剤としての縮合複素環化合物
WO2014073209A1 (ja) 2012-11-08 2014-05-15 国立大学法人山口大学 角結膜障害の治療剤
EP2964651A4 (en) 2013-03-04 2016-11-30 Brigham & Womens Hospital BMP HEMMER AND METHOD OF USE THEREOF
JP6542192B2 (ja) 2013-03-14 2019-07-10 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． Ｂｍｐ阻害剤およびその使用方法
US10702502B2 (en) 2013-05-22 2020-07-07 Yamaguchi University Inhibitor for retinochoroidal disorders
EP3201187A4 (en) * 2014-10-01 2018-04-11 The Brigham and Women's Hospital, Inc. Compositions and methods for inhibiting bmp
US20180311356A1 (en) 2015-10-19 2018-11-01 The Children's Medical Center Corporation Method to inhibit endothelial-to-mesenchymal transition
WO2017112431A1 (en) * 2015-12-24 2017-06-29 The Regents Of The University Of Michigan Method of treating heterotopic ossification
ES2963348T3 (es) 2016-06-08 2024-03-26 Clementia Pharmaceuticals Inc Métodos para tratar la osificación heterotópica
WO2020118405A1 (en) 2018-12-13 2020-06-18 Clementia Pharmaceuticals Inc. Methods for treating heterotopic ossification

Also Published As

Publication number Publication date
JP2019517528A (ja) 2019-06-24
NZ748939A (en) 2025-03-28
CN120204216A (zh) 2025-06-27
US11622959B2 (en) 2023-04-11
CA3025854A1 (en) 2017-12-14
AU2017276835A1 (en) 2018-12-13
JP2022019995A (ja) 2022-01-27
EP3468554A1 (en) 2019-04-17
US20210069152A1 (en) 2021-03-11
IL317726A (en) 2025-02-01
EP4249490A2 (en) 2023-09-27
BR112018075422A2 (pt) 2019-03-12
MX390115B (es) 2025-03-20
CL2018003502A1 (es) 2019-04-26
EP3468554B1 (en) 2023-08-09
MY200642A (en) 2024-01-08
CN109562099A (zh) 2019-04-02
US20260021073A1 (en) 2026-01-22
SG11201810658PA (en) 2018-12-28
WO2017210792A1 (en) 2017-12-14
IL295440A (en) 2022-10-01
EA201892497A1 (ru) 2019-05-31
EP3468554C0 (en) 2023-08-09
US20190216781A1 (en) 2019-07-18
US20240350457A1 (en) 2024-10-24
IL295440B2 (en) 2025-05-01
US12458626B2 (en) 2025-11-04
IL263440A (en) 2019-01-31
PH12018502563A1 (en) 2019-10-14
US10864194B2 (en) 2020-12-15
KR102486607B1 (ko) 2023-01-11
US20230285360A1 (en) 2023-09-14
MX2018015108A (es) 2019-08-29
IL295440B1 (en) 2025-01-01
MX2022001991A (es) 2022-03-11
AU2017276835B2 (en) 2022-03-31
US20240277667A1 (en) 2024-08-22
AU2022202148A1 (en) 2022-04-21
EP3468554A4 (en) 2020-01-22
IL263440B (en) 2022-09-01
KR20190017883A (ko) 2019-02-20
US12138245B2 (en) 2024-11-12
JP7023868B2 (ja) 2022-02-22
EP4249490A3 (en) 2023-12-13
AU2022202148B2 (en) 2023-08-24
ZA201808102B (en) 2024-04-24
US12201614B2 (en) 2025-01-21

Similar Documents

Publication Publication Date Title
Siddiqui et al. Management of radiation toxicity in head and neck cancers
US12458626B2 (en) Methods for treating heterotopic ossification
Silvestre-Rangil et al. Clinico-therapeutic management of osteoradionecrosis: a literature review and update
Basu et al. Toxicity with radiotherapy for oral cancers and its management: A practical approach
JP2020500864A5 (enExample)
JP2011522875A (ja) 電気的除細動を予防するためのドロネダロン
WO2020118442A1 (en) Methods for treating heterotopic ossification
BG63103B1 (bg) Използуване на алендронат за профилактика на остеопороза
Yadav et al. Rhino-orbital mucormycosis—a case report
Bain et al. The treatment of essential hypertension with pentolinium tartrate combined with Rauwolfia alkaloids
Kolondaev et al. Fibrodysplasia ossificans progressiva (clinical observation with a brief review of the literature)
HK40100879A (en) Methods for treating heterotopic ossification
KR20090103656A (ko) 섬유근육통 치료제
Mosannen et al. Fibrodysplasia Ossificans Progressiva (FOP): A Case Report with Oral and Maxillofacial Manifestations and new radiographic feature
Hong et al. H. pylori infection may cause sleep-related laryngospasm for a patient in climacteric
EA042153B1 (ru) Способы лечения гетеротопической оссификации
Ringe et al. OP0111 Treatment of established corticoid-induced osteoporosis by 3-monthly intravenous ibandronate injections
HK40006943A (en) Methods for treating heterotopic ossification
Panke et al. S80 Tuesday, October 26, 2004 Proffered papers